Haleon Kenya Ltd
Effective March 14, 2025, British pharmaceutical company GSK has rebranded its Kenyan subsidiary as Haleon Kenya Limited, aligning with its strategy to consolidate its consumer health business.
A few years ago, GSK announced its decision to halt commercial operations in the country and transition to a distributor-led model for supply.
Many saw this as a sign that the company was angling towards a complete exit but this rebrand points to a company seeking innovative strategies to have its products available in the Kenyan market in a sustainable manner.
“This transition is more than a name change; it’s a reaffirmation of our commitment to delivering high quality, science-led health solutions tailored for Kenyan consumers. As Haleon, we are strengthening our focus on innovation by developing products that combine trusted science with deep human understanding to meet the evolving healthcare needs of Kenyans. We are also expanding our local manufacturing capabilities, ensuring greater accessibility to essential health products while maintaining the highest quality of standards for the betterment of Kenya,” said Mark Pfister, Haleon General Manager for Sub-Saharan Africa.
READ ALSO: United Nations Commission Places Six new psychoactive substances under international control
Mr. Pfister has also confirmed that as the company transitions to its new name, product packaging will gradually evolve—from displaying the GSK logo to having no logo, and eventually featuring the Haleon logo.
“Consumers may notice branding differences across various assets or even among different packages of the same product on shelves,” added Pfister.
With this rebranding Haleon is expected to solidify its position as a market leader in consumer health improving on its product portfolio that includes flagship brands such as Sensodyne, Panadol, Voltaren, and Centrum.
“While there may be temporary variations in branding across different assets and product packs, Haleon’s commitment to delivering the highest standards of quality remains unchanged. Importantly, this legal name change will not have any impact on daily operations, product manufacturing, or staffing. Haleon remains fully committed to its employees and ensuring smooth business continuity,” emphasized Mark.
Did you find this informative? Subscribe for more.
Writer
APR Team
African Pharmaceutical Review team dedicated to providing the latest news, insights and developments from the pharma, biotech and medtech industries.
.jpg)